Media and Press

iMedicor Syndicates its ClearLobby Pharma Marketing Services in Alliance with MedTrust Online

Agreement Leverages MedTrust's Access to 75% of PracticingOncologists in the U.S. to Deliver Information on New Drugs andTreatments for Cancer Patients

NANUET, NEW YORK, January 25, 2010 -- iMedicor (OTCBB: VMCI) today announced that it has entered into a strategic alliance with MedTrust Online, a portal that helps cancer doctors practice the most precise medicine for their patients by linking them with the latest diagnostic and treatment strategies. The alliance will leverage MedTrust’s user base of oncologists with iMedicor’s ClearLobby profiled marketing technology.

The first program of the iMedicor / MedTrustOnline alliance is anticipated to launch this quarter. For its services, iMedicor and MedTrust will receive “click through” revenue and a portion of sales revenues generated by the alliance.

“MedTrust Online’s portal, which offers unparalleled access to U.S. oncologists, is the perfect partner for us as we bring Oncology related treatments to the U.S. market,” said iMedicor chief executive officer Fred Zolla. “The synergies between MedTrust Online’s model and the ClearLobby model make this a very promising strategic alliance and we look forward to a profitable outcome.”

MedTrust Online will also offer iMedicor’s health information exchange (HIE) functionality to its members, thereby enhancing the capabilities of Oncocentric.com, MedTrust’s proprietary technology that allows clinicians to investigate treatment options, research evidence, and to collaborate electronically on challenging cases.

"We look forward to working with iMedicor to bring new information on breakthrough drugs and treatments to our user base," said Christopher Yoo, PhD, CEO of MedTrust Online. “This partnership with iMedicor expands our capabilities to deliver the most relevant clinical content to oncologists that rely on us for the latest advances in treatments for cancer patients.”

iMedicor’s pharma marketing platform, “ClearLobby”, offers the first of its kind physician / pharma electronic communication system resulting in interactions that are much more meaningful and efficient. ClearLobby changes the dynamic of these relationships by placing control squarely in the hands of the physician. At the same time, the interaction between the physician and the pharma becomes more cost effective because ClearLobby is able to distribute critical product information and samples directly to the targeted user base.

About IMedicor:

iMedicor is the only HIPAA-compliant solution for interoperable health information exchange (HIE) that offers services at no cost to healthcare providers and patients. The iMedicor portal enables physicians, administrators and other qualified healthcare professionals to exchange medical records, files and images in a HIPAA compliant environment and allows disparate EMR (electronic medical record) systems to integrate and share data. iMedicor also delivers important information on new drugs and treatments to its members as well as the members of its syndicated partners through their ClearLobby platform. More information on iMedicor is available at www.imedicor.com.

About MedTrust Online:

MedTrust Online (MTOL) helps cancer doctors practice the most precise medicine for their patients by providing best practice knowledge about the most difficult cases. Through their portal, any oncologist can find important diagnostic and treatment information and communicate with experts about the best options for individualized therapy. MTOL brings together experts in oncology, information technology, computational biology, pharmaceutical drug development, and personalized medicine to integrate and present the latest in cutting-edge cancer care. This knowledge is presented as a free resource to doctors in a comprehensive yet concise way that is not available anywhere else. More information on MTOL is available at www.medtrust-online.com.

The statements contained herein, other than historical information, are or may be deemed to be forward-looking statements and involve factors, risks, and uncertainties that may cause actual results in future periods to differ materially from such statements. These factors, risks, and uncertainties include market acceptance of iMedicor’s products and services; the nonexclusive and terminable-at-will nature of certain of the company's partnerships and agreements; rapid technological change affecting demand for our products and services; competition from companies providing similar products and services, availability of sufficient financial resources to enable us to expand our operations, as well as other risks detailed from time to time in our filing s with the Securities and Exchange Commission.